Tag:

Diabetes

Latest Headlines

Latest Headlines

Meta-analysis: Avandia's impact on Parkinson's should spur new research

A meta-analysis of data from more than 160,000 diabetics has offered some convincing data to support the theory that PPARγ activation by glitazones--either Avandia (GlaxoSmithKline's rosiglitazone) or pioglitazone--offers significant protection against Parkinson's disease. And the researchers who did the study say that their work should help accelerate work in the field.

Israel's Oramed says $50M oral insulin deal with Sinopharm Capital-Hefei, not Guangxi Wuzhou

Israel's Oramed announced final-stage talks of a $50 million deal to sell China rights for its clinical-stage oral insulin candidate to a consortium of investors. The group consists of Sinopharm Capital Management and Hefei Life Science & Technology Park Investments and Development.

China's Guangxi Wuzhou builds stake in Israel's Oramed with diabetes in focus

China's Guangxi Wuzhou Pharmaceutical bought a 10% stake in Israel's Oramed Pharma for $52 million as well as China rights to two diabetes treatments, Reuters reported. The deal builds on a December 2014 investment of $5 million for a 7% stake in a private placement.

Survey: Hypertension, diabetes among key rising chronic diseases in China

Hypertension afflicted 25.2% of China's adult population and diabetes 9.7%, according to the state-run Xinhua news agency. That's according to a survey conducted by the National Health and Family Planning Commission over a decade that jibes with other recent public policy healthcare reform efforts by the State Council.

A heavier China drives cardio, diabetes and healthcare reforms

Rising cardiovascular disease rates in China are directly linked to a change in diet as incomes drive up demand for processed meat with high salt content. That and other dietary changes are creating a heavier population and driving government healthcare cost reforms, Xinhua reports.

Panasonic Healthcare pays $1.15B for Bayer diabetes unit, beating Sinocare

KKR-backed Panasonic Healthcare clinched a deal to buy Bayer's Diabetes Care unit in months of dealmaking that saw sources suggest an offer range of $2.3 billion to $830 million and included a reported bid by China's Sinocare for $1 billion.

Australia's Proteomics claims first predictive diabetic kidney disease diagnostic test

Australia's Proteomics International Laboratories said it has produced and validated the world's first predictive test for the diagnosis of diabetic kidney disease after a four-year study.

AZ in distribution pact with Dr. Reddy's to extend reach in India

AstraZeneca Pharma India has signed up Dr. Reddy's Laboratories to distribute its diabetes medicines Riax and Riax-M in India as domestic and foreign companies look for advantages in a crucial and sharply competitive market where generic activity is on the rise.

Sinocare said to bid $1B for Bayer diabetes devices, piping Panasonic

China's Sinocare reportedly has made a $1 billion bid for Germany-based Bayer's diabetes devices. As maker of blood-sugar monitors, Sinocare would be challenging a broader based company, Panasonic Healthcare, already months into discussions with the seller.

Johns Hopkins team finds a new drug target for diabetes

Scientists at Johns Hopkins say they've identified a link between high blood sugar and an interference with mitochondria that could make for a prime new target in the field of diabetes drug research.